Fritillariae Thunbergii Bulbus (FTB) has been widely used as an antitussive herb for thousands of years in China. However, FTB’s traditional uses, chemical compounds and pharmacological activities have not been systematically reviewed. This study aimed to review its traditional uses, phytochemistry, pharmacodynamics, pharmacokinetics and toxicity. We searched the Encyclopedia of Traditional Chinese Medicine to explore the historical records which indicate that it acts to clear heat, resolve phlegm, relieve cough, remove toxicity and disperse abscesses and nodules. We searched 11 databases to identify potential phytochemical or pharmacological studies. Characteristics of its chemical constituents, pharmacological effects, pharmacokinetic and toxicity were descriptively summarized. A total of 9706 studies were identified and 83 of them were included. As a result, 134 chemical constituents were identified, including 26 alkaloids, 29 compounds found in essential oils, 13 diterpenoids, two carbohydrates, two sterols, 18 amino acids, six nucleosides, four nucleobases, four fatty acids, three lignans, and 27 elements. Thirteen pharmacological effects of FTB were identified, including anti-cancer, tracheobronchial relaxation, antitussive, expectorant, anti-muscarinic, anti-inflammation, anti-thyroid, regulation of blood rheology, antiulcer, anti-diarrhea, pain suppression, antioxidation and neuroprotection. These pharmacological activities may be mainly attributed to the alkaloids in FTB. Further phytochemical, pharmacological and network pharmacological studies are recommended.

Qigong and Tai Chi (QTC) have been adopted by cancer patients as the complementary treatment to their conventional care. This umbrella review aimed to evaluate the clinical effectiveness of QTC in cancer patients’ quality of life (QoL) and its safety. Twenty-five databases were searched from their respective inception to March 2025. Systematic reviews (SRs) and meta-analyses of randomized controlled trials (RCTs) assessing cancer patients’ QoL after practicing QTC were included. The search strategy included Qigong, Tai Chi, quality of life, cancer, systematic review, and meta analysis. The extracted data was analyzed using standardized mean difference, mean difference, or odds ratio with 95% confidence intervals. Nine SRs were included in the qualitative analysis, and six of the SRs were included for the meta-analyses. Results showed that QTC may improve cancer patients’ overall QoL, physiological scores (physical functioning, fatigue, and sleep quality), psychological scores (mental health and anxiety), and immunity, compared to the control groups. However, meta-analyses did not demonstrate significant differences in subgroup analyses of depression, although it showed that QTC may reduce depression in cancer patients. No serious adverse events of QTC were reported. QTC can be considered a safe intervention method for improving QoL in patients with cancer. Due to substantial heterogeneity, more rigorously-designed RCTs on QTC for cancer patients should be conducted, focusing on standardizing QTC practices and QoL instruments to assess QTC effects. CRD42021253216.

A classic herbal formula Guizhi Fuling Wan (GFW) has been used for managing menopausal hot flushes (MHFs), but the evidence across different study types has not been systematically summarized. This project investigated the clinical effects, phytochemistry, pharmacodynamics, and potential mechanisms of actions of GFW on the causative target proteins potentially driving MHFs. Twenty English and Chinese databases were searched for relevant clinical and experimental studies. A total of 12,988 studies were identified, of which 46 were included. Seven clinical studies demonstrated GFW had no statistically significant changes in the frequency and severity of MHFs; however, it could improve peripheral blood flow in the fingertips, jaw, and toes. Thirty-five studies on phytochemistry identified 169 chemical compounds of GFW. Four experimental studies revealed GFW’s therapeutic effects (e.g., normalize calcitonin gene-related peptide (CGRP) level) and potential target protein/cytokine (estrogen receptor beta (ESR2) with genetic variation, CGRP receptor, and interleukin-8) on MHFs. Therapeutic effects across different study types were inconsistent, possibly due to the dose difference and genotype variety of ESR2 in the human population. Further clinical and experimental studies, as well as biochemical investigation on the mechanisms of actions of GFW, are recommended.